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Serological surveys with multiplex bead assays can be used to assess seroprevalence to
multiple pathogens simultaneously. However, multiple methods have been used to generate
cut-off values for seropositivity and these may lead to inconsistent interpretation of results.
A literature review was conducted to describe the methods used to determine cut-off values
for data generated by multiplex bead assays.
Methodology/Principal findings
A search was conducted in PubMed that included articles published from January 2010 to
January 2020, and 308 relevant articles were identified that included the terms “serology”,
“cut-offs”, and “multiplex bead assays”. After application of exclusion of articles not relevant
to neglected tropical diseases (NTD), vaccine preventable diseases (VPD), or malaria, 55
articles were examined based on their relevance to NTD or VPD. The most frequently
applied approaches to determine seropositivity included the use of presumed unexposed
populations, mixture models, receiver operating curves (ROC), and international standards.
Other methods included the use of quantiles, pre-exposed endemic cohorts, and visual
inflection points.
Conclusions/Significance
For disease control programmes, seropositivity is a practical and easily interpretable health
metric but determining appropriate cut-offs for positivity can be challenging. Considerations
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for optimal cut-off approaches should include factors such as methods recommended by
previous research, transmission dynamics, and the immunological backgrounds of the pop-
ulation. In the absence of international standards for estimating seropositivity in a popula-
tion, the use of consistent methods that align with individual disease epidemiological data
will improve comparability between settings and enable the assessment of changes over
time.
Author summary
Serological surveys can provide information regarding population-level disease exposure
by assessing immune responses created during infection. Multiplex bead assays (MBAs)
allow for an integrated serological platform to monitor antibody responses to multiple
pathogens concurrently. As programs adopt integrated disease control strategies, MBAs
are especially advantageous since many of these diseases may be present in the same popu-
lation and antibodies against all pathogens of interest can be detected simultaneously
from a single blood sample. Interpreting serological data in a programmatic context typi-
cally involves classifying individuals as seronegative or seropositive using a ‘cut-off’,
whereby anyone with a response above the defined threshold is considered to be seroposi-
tive. Although studies increasingly test blood samples with MBAs, published studies have
applied different methods of determining seropositivity cut-offs, making results difficult
to compare across settings and over time. The lack of harmonized methods for defining
seropositivity is due to the absence of international standards, pathogen biology, or assay-
specific methods that may impact resulting data. This review highlights the need for a
standardized approach for which cut-off methods to use per pathogen when applied to
integrated disease surveillance using platforms such as MBAs.
Introduction
Neglected tropical diseases (NTDs) and vaccine preventable diseases (VPDs) cause a signifi-
cant burden on populations in developing countries, and effective surveillance plays an impor-
tant role in the control and elimination of these diseases. Despite the geographical overlap of
co-endemic tropical infections in many regions of the world, surveillance efforts have often
focused on separate diseases [1]. Integrated approaches to controlling tropical diseases have
been implemented in some programmatic settings. However, asymptomatic infections, poor
health seeking behaviour, long latency periods, and inconsistent reporting of cases make effec-
tive monitoring difficult when relying on passive case detection alone [2].
Serological surveys can be highly informative when assessing the prevalence of diseases or
vaccine coverage within a population [3], since antibodies can be used to detect asymptomatic
infection and historical exposure to natural infection or a vaccine [1,4]. As integrated
approaches to the management of NTDs are being adopted, multiplex bead assays (MBAs)
provide a platform to monitor exposure to multiple pathogens from a single blood sample [5].
MBAs typically measure antibody response in median fluorescence intensity (MFI), which is
proportional to the levels of antigen-specific antibodies (most commonly IgG) in the blood
[6]. Cross-sectional and longitudinal serological data have been used in various public health
settings, including evaluating mass drug administration (MDA) campaigns[7,8], assessing
changes in population level exposure [9], monitoring transmission patterns [10,11], assessing
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the impact of vaccine program coverage [12], and determining prevalence thresholds for con-
firming disease elimination [7,13].
While serological surveys using MBA provide efficient and cost-effective benefits to inte-
grated pathogen monitoring, a challenge remains in data interpretation. In analysis, the MFI
values are often used to estimate the seroprevalence to a particular antigen through calculated
or arbitrary cut-off values to define seronegative and seropositive populations. In some cases,
higher MFI values are assumed likely to represent more recent or repeated exposure [14,15].
Prior knowledge of specific antibody titres and associated kinetics would be helpful in more
accurately interpreting the data. For this review we consider ‘seropositive’ as a general term
that could represent either current or previous infection or vaccination, without interpretation
pertaining to specific antibody kinetics or longevity.
The use of a binary seropositivity endpoint allows translation of continuous assay-specific
MFI values into a common epidemiologic metric: seroprevalence. Different approaches have
been used to define a seropositive response, though the rationale or implication of the method
choice is rarely made clear. The choice of approaches used are likely the result of a standard
laboratory approach, adopting methods applied in previous studies, or simply ease of use.
Antibody responses to different pathogens are intrinsically diverse, making it plausible that
specific cut-off methods are better suited for specific antigens or situations. Understanding
current approaches used for determining seropositivity is a crucial step in developing stan-
dardised methods, ensuring appropriate interpretation of the data to support more robust pro-
grammatic decision-making. To address this evidence gap, a literature review was performed
of existing methods for determining cut-off values for the assessment of seroprevalence for
NTDs and VPDs with MBA.
Methods
Review of literature
We conducted a literature review on PubMed for articles published between January 1, 2010
and January 31, 2020. Search terms included “multiplex bead assays” + “serology” + “cut-off”.
Studies were excluded if they were not in a published journal (e.g. clinical case reports or con-
ference abstracts), published prior to 2010, did not include serological targets for NTDs,
malaria or VPDs, or used serological tools specifically for clinical diagnosis. In total, the initial
search identified 308 articles of which 253 articles were not included based on title and
abstract. Fifty-five articles met the inclusion criteria for full screening which included serology,
NTDs (as defined by the World Health Organization and/or PloS NTD lists)[16], malaria,
VPDs in tropical regions, and the use of MBA (Fig 1). Articles were then selected if they
described cut-off methods using data based on quantitative antibody levels from MBA plat-
form for the application to seroepidemiology.
Results
Literature review—Applied methods of determining seropositivity
Eight cut-off approaches were identified based on literature reviewed, with seven methods
being applied that provided valid cut-off values (Table 1). A list of all the articles reviewed
using each method, antigens within the study, and population origins are listed in S1 Table.
Examples of applied methods in different public health settings (Table 1) and the advantages
and disadvantages of the different methods (Table 2) are described below.
Presumed unexposed. Cut-off values can be determined by a population that has no
expected exposure to the pathogen of interest. Depending on the pathogen, these populations
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are typically selected based on self-reported claims of no travel or no recent travel history to
endemic countries. For NTDs, seronegative populations have been chosen from non-endemic
regions, including the United States, Sweden, and Japan [6,21,23,29]. When applying pre-
sumed unexposed populations to define cut-offs, a pre-specified number of standard devia-
tions (usually three) above the mean of the MFI values with background subtracted (MFI-bg)
in the presumed unexposed population are used. Any result above that MFI-bg value is consid-
ered as seropositive, and the number of standard deviations used may depend on stringency of
identifying seropositives. Use of presumed unexposed populations to determine cut-off values
provides a viable option where a large majority of the study population is exposed due to high
transmission. In such settings, an endemic seronegative population, as required by other com-
monly used approaches described below, may be difficult to identify due to small numbers.
However, there are several potential sources of bias to using a presumed unexposed popula-
tion to derive seropositivity. Cut-off values from presumed unexposed populations run the
risk of bias as the immunological exposure of the populations being compared may not accu-
rately represent the immunological history of the sample population. This could be due to fac-
tors such as genetic differences affecting immune responses, age differences between
presumed unexposed and study population, nutritional status, and/or co-infections of multiple
diseases [30–32]. As a result, cut-off values defined by presumed unexposed populations may
be artificially low, leading to inflated prevalence estimates. Moreover, differentiating between
active and historical infections may not be captured by an overly sensitive cut-off [21]. Con-
versely, while presumed unexposed populations by definition have no exposure to the infec-
tion being monitored, some individuals may have had unknown contact with the pathogen
of interest or cross-reactive pathogens that may generate elevated cut-off values if not
excluded.
Fig 1. Flowchart of article selection for inclusion in literature review. The PubMed search identified 308 articles
with 253 being excluded because they did not meet the inclusion criteria. After review, 55 articles were retained for
analysis.
https://doi.org/10.1371/journal.pntd.0009457.g001
PLOS NEGLECTED TROPICAL DISEASES Review of approaches to define tropical disease seroprevalence using multiplex bead assay
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009457 June 28, 2021 4 / 16
Receiver operating characteristic (ROC) curve. ROC curves can be used to generate cut-
offs by plotting the true positive rate (sensitivity) against the false positive rate (specificity)
[33]. The optimal cut-off is considered the value that provides the best discrimination between
the true seronegative and seropositive populations, or a cut-off that gives equal weight to sensi-
tivity and specificity [34]. Studies have considered presumed unexposed populations, as
defined above, as the true negative population, while true positive populations have been con-
sidered as those being either a clinically confirmed case or according to established laboratory
gold standards for that pathogen [4,8].
A method with perfect discrimination creates an ideal cut-off between the two populations
with no overlap [35], however, it can be rare to observe such separation in the general popula-
tion (Table 2). Accurate ROC curves to define cut-offs rely on the availability of true negative
and true positive reference-populations which are seldom available in practice. Additionally,
the reference population used to delineate true positive/negative individuals may also bias
results, similar to the disadvantages mentioned for presumed unexposed populations [36].
Table 1. Examples of several applied cut-off approaches using MBAs in various settings for NTDs and VPDs. MBA used, location, cut-off approach, and the goal of
the program are provided in this table to demonstrate the application of cut-off methods in different settings. Where, N refers to the number of studies employing the
method and SD refers to standard deviations.
Disease Location Additional cut-off details Goal (study Ref)
Presumed unexposed (N = 23)






Disease monitoring after MDA [18]
Trachoma Haiti Examining MBA as a monitoring tool [19]
Amoebiasis Haiti Disease dissemination [20]
Leishmania Kenya Japan/ mean +3SD Application of multiplex assays [21]
Receiver Operating Curves (N = 15)
Yaws Ghana Clinically confirmed negatives and positives. Evaluate antibody response in MBA [4]
Measles Kenya Gold standard lab technique confirmation. Assess schistosomiasis impact on vaccine preventable diseases [22]
Strongyloidiasis Cambodia Presumed unexposed population used for ROC
curve
Application of an integrated, multiple disease survey [23]
Mixture Models (N = 14)
Lymphatic
Filariasis
Kenya Mean of negative component + 3SD Validation of MBA to lymphatic filariasis [21]
Chikungunya Haiti Mean of negative component + 2SD Estimate exposure [24]
International Standards (N = 6)
Tetanus Cambodia
Tanzania
>100 MFI units = 0.01 IU/ml = seroprotective Monitor progress of elimination [12]
Assess immunity gaps [25]
Quantile (N = 1)
Influenza Vietnam No distinct cut-off, use of antibody titres Estimating population-level antibodies [26]




Impartial (independent) individuals to determine
cut-off
Defining seropositivity thresholds for elimination programs [27]












Longitudinal cohort Understanding force of transmission among children through seroconversion
rates [28]
https://doi.org/10.1371/journal.pntd.0009457.t001
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Finite mixture model. A mixture model is a probabilistic model that assumes the pres-
ence of at least two normally distributed subpopulations, or components, within the sample
population [37]. These components represent underlying populations of varying antibody
responses [21,38,39]. The negative population are assumed those within the lowest distribution
of MFI values. The cut-off value can be determined using estimated parameters (i.e. mean and
standard deviation) of the lowest component specified by the mixture model [40]. Commonly,
the cut-off value is then calculated similar to the presumed unexposed approach, using the
mean plus a pre-defined number of standard deviations [21,36,41]. Alternatively, mixture
models can use joint probabilities of classifying individuals with specific antibody levels as
either seropositive or seronegative to specify appropriate cut-off values [39].
Mixture models can, theoretically, provide cut-off values that more closely resemble the
target population immunity with a distribution of MFI values representing seronegative indi-
viduals within the target population. This is advantageous because baseline seronegative anti-
body concentrations have been shown to differ between populations due to transmission
history of the pathogen of interest, circulating co-infections, and any population-specific
genetic factors [21]. Additionally, multiple component mixture models have the potential to
identify exposure history. For example, in a mixture model with three components, the lowest
component could be considered as seronegative, the middle component as an “indefinite/bor-
derline” or past exposure history group, and the highest component as seropositive or recent
exposure group [21,42]. However, the choice of how many components is also a practical chal-
lenge for different pathogens and may rely on understanding antigen-specific immunological
response. Mixture models can also be fitted to different distributions depending on the pattern
of responses of the pathogen of interest, such as in the case of VPDs and distinguishing
between stronger antibody responses in naturally infected compared to vaccinated individuals
[43,44].
Table 2. Summary of Advantages and Disadvantages of different seropositivity cut-off methods.
Cut-off Method Advantages Disadvantages
Unexposed or presumed
unexposed population
- Known seronegative population
- Can be used with other classification methods that require
a true seronegative population
- Cut-offs may not reflect true immunity of target population, leading
to potential misclassification
- Requires obtaining a presumed unexposed population
- Only appropriate for certain diseases which are absent in the
population from where negatives are selected
- Potential for cross reactivity
Mixture Model -Generates cut-off using statistical modelling without
external samples needed
-Determines an endemic, seronegative population within
sample
- May not be appropriate in very high or very low transmission settings
- Possibility of an indeterminate range of overlapping seronegative and
seropositive individuals
ROC Curve - Robust cut-off generated from true positives and true
negatives
- Often requires “gold standard” confirmation of positive and negatives
International Standards - Provided by WHO
- Universal method of categorizing seropositivity to enable
standardization across assays and laboratories
-Fixed cut-off values may not accurately capture differences in natural
and vaccinated responses due to its diagnostic purpose.
-Not available for many NTDs.
Quantiles -Visual distribution of MFI intensities and allows for
comparison of means
-Choice of which quantiles to use that accurately reflects serostatus
must be determined by investigator
Visual Inflection Point -Simple method -Arbitrarily decided by investigator
-May need a statistical method to confirm
- Potential for poor reproducibility across settings
Pre-exposed endemic cohort -Provides a presumed seronegative population from the
population of interest
-Requires longitudinal data and following individuals who were disease
free and later developed disease.
-Using MFI values of children may not accurately represent MFI values
in adults
https://doi.org/10.1371/journal.pntd.0009457.t002
PLOS NEGLECTED TROPICAL DISEASES Review of approaches to define tropical disease seroprevalence using multiplex bead assay
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009457 June 28, 2021 6 / 16
Mixture models may not be appropriate in areas of high transmission or very low transmis-
sion [11]. When only one component is observed (e.g. everyone is exposed or unexposed) or
when components have significant overlap (e.g. population with large portion of historical
exposure or have received treatment), it becomes difficult to identify a reliable cut-off and clas-
sify individuals as seronegative or seropositive based on probabilities [21]. Moreover, choice of
distribution for fitting mixture model and resulting cut-offs may be rejected if they do not
agree with components upon visual inspection and investigator judgment. Co-circulating
pathogens that may result in cross-reactivity of antibody response to the antigens being
assayed can also be difficult to separate using mixture models [45].
International standards and units. International Standards or International Reference
Materials of the World Health Organization (WHO) are used as a simple method for a uni-
form classification system. This allows comparison of biological targets, such as vaccine
induced antibodies, across populations using pre-set cut-off values [46]. This approach
requires standard reagents to generate an assay-specific standard cut-off for each of the differ-
ent antigenic targets which can then be applied consistently across all settings. The main
advantage includes the facilitation of between-setting comparisons. However, occasional pre-
set international standard cut-off values have been found to overestimate the size of the sero-
negative population [47] or to classify individuals to incorrect serostatus groups [48]. This
could be related to the fact that international standards are decided a priori and without con-
text to the populations of interest. Therefore, any potential biases when applying the standard
due to population specific genetics are not accounted for, unless they were developed using
populations from all endemic countries. Moreover, the international standards may have been
developed for specific applications, such as providing a clinical endpoint, and may be less suit-
able in a seroepidemiological context [37]. For example, international standards for rubella
have been found occasionally to overlook potential immunity, due to high cut-offs set by man-
ufacturer assays to avoid false negatives [37].
Quantiles. Cut-offs can be determined through rank statistics that partition MFI values
into quantiles of equal probabilities. Quantiles have been used outside the context of NTDs,
such as understanding viral loads in influenza [26]. Theoretically, higher quantiles could be
interpreted as seropositive, while lower quantiles would be interpreted as seronegative. The
partitions of quantiles may furthermore represent different levels of seropositivity, such as
populations of non-exposure, of historical exposure, repeated exposure resulting in ‘boosting’
of antibodies, or populations of active or recent infections. Quantiles require the analyst to
subjectively, or based on biological and/or clinical knowledge, choose the number of quantiles
for the analysis and then to specify which quantiles are seropositive or seronegative. Addition-
ally, they may assume homogeneity of exposure in quantile groups that could lead to inaccu-
rate estimations [49].
Visual inflection point (VIP). A single study looked at using crude cut-offs determined
by visually examining inflection points within MFI distributions in graphs. Migchelsen et al.,
in exploring options for determining trachoma cut-offs, did a convenience sample of impartial
individuals to visually inspect data curves to determine an inflection point [27]. The final cut-
off was considered to be the average of values reported by the participants. The mean reported
cut-off values were similar to cut-offs from the mixtures models as applied to the same dataset
[27]. Moreover, the process is more straightforward and intuitive compared to the mixture
model approach.
Use of VIP relies on pattern recognition to subjectively generate cut off values, and inflec-
tion points may be biased based on groups of individuals asked. In addition, VIP should ideally
use impartial participants and mask antigens to reduce bias. Sampling more individuals to
determine the inflection point may improve the precision of the estimates of VIP, but
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recruiting a large number of participants can be time-consuming and challenging in certain
situations. With this method there are problems with reproducibility, accuracy is likely associ-
ated with the degree of separation between the negative and positive distributions.
Pre-exposed endemic cohort. While serological assays are frequently cross-sectional, lon-
gitudinal surveys that have obtained serological data before and after infection can create a
cut-off based on the change of MFI values before compared to after exposure. Arnold et al.
have explored this cut-off method (termed “presumed unexposed” within their study) for
enteric pathogen antibody responses among children from Kenya and Haiti [28]. The resulting
cut-offs were comparable to both mixture models and presumed unexposed referent popula-
tions, but this method also enabled estimation of cut-offs for particularly high-transmission
pathogens where other methods failed. In high transmission settings, fitting mixture models
can be challenging in the case where distinct components are not present (see mixture model
section above), while cut-offs of presumed unexposed from may not reflect immunological
background of study population (see presumed unexposed section). A negative population to
use for cut-off determination was generated from MFI values of<1-year-olds who later sero-
converted (based on a conservative +2 increase on a log10 scale or a 100-fold increase in MFI).
The cut-off was determined by taking the mean of the distribution of measurements before
these<1-year-old children seroconverted and then adding three standard deviations.
Identifying a pre-exposed endemic cohort population using measurements from individu-
als who subsequently seroconvert may be useful for longitudinal studies that have collected
data on individuals prior to a point change to seroconversion or infection status. However,
using MFI values of unexposed infants may not represent the true seronegative MFI values in
the adult population due to inherent differences in the immature and mature immune systems.
Maternal antibodies may also be present in infants, leading to potentially higher responses in
infants that reflects the exposure history of the mother not of the child. The choice of antibody
level increase required to identify “pre-exposed endemic cohort” is a qualitative decision, and
so accompanying sensitivity analyses of alternate increases could prove useful [28]. Addition-
ally, longitudinal monitoring may not be logistically feasible for many surveillance programs
administering cross-sectional surveys.
Discussion
As programs implement integrated approaches to controlling infectious diseases, effective
monitoring is crucial. Serological MBAs provide a convenient method for understanding the
population-level burden for multiple diseases simultaneously [50]. This is particularly relevant
for those pathogens with long latency periods or with symptoms not sufficiently acute to
prompt care-seeking. MBAs can also generate data at a comparatively low cost [1], making it
an efficient tool for integrated surveillance of tropical and vaccine preventable diseases. Assess-
ing disease burden through seropositivity is valuable and a more programmatically interpret-
able metric compared to the continuous MFI values. Additionally, assay and differences in
bead coupling concentrations or methods between studies will lead to variability in overall
magnitude of antibody levels measured, making the direct comparisons of MFI values almost
impossible without appropriate assay standards or a standard metric, such as seropositivity.
However, use of seropositivity requires careful consideration of how to define appropriate cut-
off values that can meaningfully identify exposed individuals and those with disease burden
according to public health programmatic guidelines.
This review highlights several approaches for determining seropositivity cut-offs. The most
frequently used approaches were presumed-negative populations, ROC curves, mixture mod-
els, and international standards. Other approaches included quantiles, pre-exposed endemic
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cohort, and visual inflection points. Each method has its respective advantages and disadvan-
tages. For all methods that rely on external samples, such as presumed unexposed population
or ROC curve, it is important to acknowledge that antigen-bead coupling efficacy may differ
between bead batches and, if not run on the same bead set, potential differences in cut-off val-
ues may be observed. In addition, instrumentation differences may impact the stability of the
cut-off values. Under these circumstances, additional adjustments to the MFI values maybe
required for appropriate comparisons. Additional factors important to consider in identifying
the most appropriate method for any given context include: the availability of confirmed sero-
negative and seropositive populations that are necessary for methods such as ROC and pre-
sumed unexposed; use-case scenarios based on program targets or goals; transmission
intensity factors that impact the seronegative and seropositive distributions for methods that
assume sub-populations; methods previously used in similar settings and diseases; and com-
plexities in certain pathogen-host immunobiology that queries the suitability of strict cut-offs
(Box 1).
Box 1: Summary of factors to consider and complexities in choosing
cut-off methods
Availability of Seropositive and Seronegative Populations
The availability of expected true seropositive and seronegative populations through
screening, clinical confirmation, populations from countries without transmission, or
gold standard laboratory techniques justifies the use of presumed unexposed approach,
ROC curves, and other supervised classification methods. Additionally, if there are large
differences in endemicity within a country, populations from low or non-transmission
areas could serve as a seronegative population. Having the presence of seropositive and
seronegative populations does not the exclude using other methods, however. Addition-
ally, precision, quality, and interpretation of cut-off values are impacted by a variety fac-
tors that should be taken into consideration along with the method of determining cut-
offs.
Large sample sizes
As with many statistical methods, larger sample sizes allow for a better estimation of the
target population, improving both sensitivity and specificity. Additionally, certain cut-
off methods, such as mixture models, can be achieved with larger sample sizes. Smaller
sample sizes may require fitting different distributions [56].
Use-case scenarios
Cut off methods can be chosen depending on the goal and design of the study or the pro-
gram. For example, cut-off methods such as ROC with high sensitivity or specificity may
be preferred in the case of assessing program coverage [11, 19]. Cut-off methods such as
quantiles or mixture models with several components that can identify multiple levels of
seropositivity may be chosen when trying to understand geographic transmission
patterns.
Literature past precedent or international guidelines
Decision to use a certain method could be influenced by or borrowed from other studies
that focus on biologically similar diseases. This also includes international guidelines
that provide cut-offs for vaccine preventable diseases. This consideration offers a simple
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and convenient rationale to choosing a certain cut-off method given that the cut-off has
already been established. Making comparisons between studies using similar antigens
may also determine the use of a certain cut-off method.
Transmission Dynamics
The justification of using certain cut-off methods may depend on the level of transmis-
sion of the pathogens. Mixture models and quantiles are more appropriate in transmis-
sion areas where the seropositive and seronegative components have some separation
evident in the MFI distributions.
Complexity of the immunology of host-pathogens interactions
The use of statistical methods is an attempt to reflect a biological process in terms of
exposure or lack of exposure. While statistical methods for cut-offs are important in
determining seropositivity, weight should also be placed on understanding the complex
immunology of the NTD of interest and the immunological background of the popula-
tion. Incomplete understanding of serologic response and other immune mechanisms
against pathogens of interest may impact interpretation of prevalence estimates gener-
ated from cut-offs [47]. For example, population level antibodies due to partial or wan-
ing immunity could make it difficult to define a strict cut-off value for seropositive and
seronegative groups [11]. It may also be unclear whether responses observed during a
chronic infection ever revert to a seronegative state [35]. Therefore, using an indetermi-
nate range or comparing the mean MFIs in these circumstances maybe more appropri-
ate than enforcing a strict cut-off value [59, 60].
Antigen and antibody dynamics
Antibody responses are inherently noisy and imposing a strict cut-off may lead to mis-
classification [61]. Furthermore, antibody longevity may impact seropositivity classifica-
tion [60, 62]. Coinfections can also be difficult to detect and separate, as certain
pathogens with high titres can dominate detection assays [63].
In addition, antibody dynamics in terms of boosting and decay rates post infection
should be taken into consideration. For example, as control programs lead to less disease
exposure in populations, lower amounts of infection-specific antibodies circulate in the
population and are replaced by residual antibody responses [64]. Roscoe et al. noted S.
stercoralis antibodies decreased over time but remained above cut-off values a year and a
half after successful treatment [65]. When determining prevalence estimates with cut-off
values, some of these responses may actually be the result of cleared infections with
residual antibodies.
Moreover, the dynamics of antibody-antigen interactions within age groups such as chil-
dren and adults should be considered when interpreting cut-off values as they have been
shown to differ [66]. For instance, cut-off values determined from a population of chil-
dren may not be appropriate for the entire population age range when assessing preva-
lence of certain pathogens as children’s immune systems are predominantly short-lived
B-cells, while antigen presentation and helper T-cell function are more developed in the
immune systems of adults[11, 67, 68]. Lastly, the inherent nature of antibody classes,
such as IgG vs IgM, may be interpreted differently regardless of cut-off method [69].
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As more programs implement serological surveillance strategies for neglected tropical dis-
ease monitoring, it is possible that new cut-off methods will be developed and applied. Alter-
natively, other classification methods without a distinct cut-off, such as K-means clustering,
aims to separate high dimensional data (i.e. multiple antigenic targets for the same pathogen)
into different clusters of MFI values to represent seronegative and seropositive states could be
implemented [51,52]. Use of multiple target antigens will increase the likelihood of detecting
previous exposure to infection as well as reducing the likelihood of non-reactivity due to
sequence variation in single antigenic targets and differential immunogenicity. However, in
multi-disease panels, antigens need to be well-defined in order to avoid potential cross-reactiv-
ity that could lead to issues of inaccurate or false results due non-specific binding [53]. Fur-
thermore, heterogeneity of individual responses that influence antibody levels apart from
pathogen exposure, e.g. nutrition or health conditions, can cause increased immunoglobulin
in sera, such as hypergammaglobulinemia [54]. Refining statistical techniques that allow
assessment of multiple and/or combinations to generate seroprevalence will also be of benefit
and aid in interpretation of data [55,56].
Within our review, there are several limitations. Our search criteria targeted serological
cut-offs according to WHO and PLOS definition of NTDs and VPDs, specifically in PubMed
and in English. However, there may have other methods to determine serological cut-offs for
diseases were not included in this review from other databases and also outside the specific
timeframe we examined. Additionally, the search criteria focused only on the term “cut-off”,
which may have overlooked similarly terminology, such as “threshold” or “inflection point”
that could have provided additional cut-off approaches. Our study also reviewed cut-offs pri-
marily from MBA and enzyme-linked immunosorbent assay (ELISA) platforms due to our
search criteria and did not include other serological or commercial immunoassays that may
have used other approaches. However, any additional methods that we could have identified
are unlikely to change the conclusions of this work.
International standards based on a large sample of reference standard sera from individuals
in known elimination settings will be needed to define universal cut-offs and make program
decisions based on specific levels of seropositivity. This would require procuring sera from
clinically confirmed individuals with infection and those without infection from a geographi-
cally representative number of endemic countries to ensure sufficient diversity of immunologi-
cal responses, as were recently done for human African trypanosomiasis [57, 58]. Sera from
these candidates would then be characterized by different immunological tools to determine
consistent measurements of immunological activity (with context to programmatic use) across
all platforms in the form of international units. In the absence of these metrics for NTDS,
ROC curves with confirmed positives and negatives from the study population are recom-
mended as they would likely generate the most representative cut-offs that consider immuno-
logical and genetic backgrounds of the population. Without control sera mixture models are
Laboratory technique and design
Although not a focus of this paper, laboratory techniques impact the quality of MFI val-
ues. Thus, the generation of good quality cut-off values and resulting prevalence esti-
mates require appropriate assay validations with sufficient quality control protocols [70].
Additionally, cut-off thresholds are dependent on specific coupling conditions [71], and
bead consistency is an absolute requirement for the generation of precise cut-off values,
regardless of the cut-off determination method.
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recommended as they may provide statistically robust cut-offs when adjusting for transmission
intensity by using appropriate distributions and number of components to identify seroposi-
tives. In the context of integrated disease surveillance, the recommendation for an appropriate
cut-off method to determine seroprevalence should additionally consider the antigen being
assessed, the optimal data that is the closest reflection of true population prevalence, and other
important factors and complexities that could impact decision of cut-off method listed in
Box 1.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily rep-
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